Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma

Blood Adv (2024) 8 (2): 484–496.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals